Management of Cancer Therapeutics-Related Cardiac Dysfunction

Abstract

Improvements in detection and treatment of cancer have resulted in a significant increase in cancer survivors. However, cancer survivorship comes with long-term risk of adverse effects of cancer therapies, including cardiomyopathy, heart failure, arrhythmias, ischemic heart disease, atherosclerosis, thrombosis, and hypertension. There is a renewed interest in understanding the pathophysiology of cancer therapeuticserelated cardiac dysfunction. In recent years, efforts have been directed to the management of cancer therapeuticserelated cardiac dysfunction. This article discusses the pathophysiology and molecular mechanisms that contribute to cancer therapeutics-related cardiac dysfunction and presents an napproach to the evaluation and treatment of these patients.

Keywords: Anthracyclines; Cancer therapy–mediated cardiotoxicity; Chemotherapy-induced cardiomyopathy; HER2-targeted therapies; Radiotherapy-induced cardiotoxicity; Renin-angiotensin inhibitors; Trastuzumab; β-Blockers.